LumiThera Inc. is the recipient of a $1.5 million grant from the National Eye Institute in support of a clinical trial investigating a new treatment for diabetes-related ocular pathology, according to a press release.
The grant supports the photobiomodulation reduction in macular edema, or PRIME, trial. The trial is a prospective, randomized, multicenter trial investigating the effects of the Valeda light delivery system in patients with diabetic retinopathy and diabetic macular edema. The trial is subject to FDA investigational device exemption approval.
"We will be evaluating if PBM can
Uncategorized